An epigenetic four-lane route to camouflage for cancer cells
Cancer Cell · 2026-07 · 44 (7) · 1341-1342
DOI: 10.1016/j.ccell.2026.05.017 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancer Cell, 2026-07. Verfasst von Lorenzo Galluzzi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: deadoc80@gmail.com. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Neoplasms, Tumor Escape. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Malignant cells can exploit numerous mechanisms to evade anti-tumor immunity. In this issue of Cancer Cell, Foidart et al. demonstrate that neoplastic cells undergoing whole-genome doubling acquire epigenetic changes that actively suppress antigen presentation, hence effectively hiding from recognition and elimination by CD8+ T lymphocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: deadoc80@gmail.com.
- Italian Institute for Genomic Medicine, c/o IRCSS Candiolo, Torino, Italy; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
- Italian Institute for Genomic Medicine, c/o IRCSS Candiolo, Torino, Italy; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy. Electronic address: iliovit@gmail.com.
Zitieren
APA
Galluzzi, L., Manic, G., & Vitale, I. (2026). An epigenetic four-lane route to camouflage for cancer cells. Cancer Cell, 44(7), 1341-1342. https://doi.org/10.1016/j.ccell.2026.05.017
Vancouver
Galluzzi L, Manic G, Vitale I. An epigenetic four-lane route to camouflage for cancer cells. Cancer Cell. 2026;44(7):1341-1342. doi:10.1016/j.ccell.2026.05.017
BibTeX
@article{Galluzzi2026,
author = {Galluzzi, Lorenzo and Manic, Gwenola and Vitale, Ilio},
title = {An epigenetic four-lane route to camouflage for cancer cells},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {7},
pages = {1341--1342},
doi = {10.1016/j.ccell.2026.05.017}
}
EUVIMED